Recent Updates
Recently added Catalysts
ERAS Positive Sentiment

Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Monday, August 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Erasca, Inc. has announced inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). This move is part of their strategy to attract and retain talent as they focus on developing therapies for RAS/MAPK pathway-driven cancers. The announcement highlights the company's commitment to advancing precision oncology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Erasca is focused on precision oncology.
  • The company is actively developing therapies for cancer.
  • Inducement grants may attract talented professionals.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+770%
120-day peak, hindsight
Typical move
20.6%
average across 3 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
Naporafenib
Phase 3 · Advanced or Metastatic NRAS-mutant Melanoma

Full Press Release Details

SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that, in connection with the

Frequently Asked Questions

What are inducement grants?

Inducement grants are stock options or equity awards given to attract and retain talent.

What is Nasdaq Listing Rule 5635(c)(4)?

This rule allows companies to grant stock options to new employees without shareholder approval.

What is Erasca focused on?

Erasca is focused on developing therapies for RAS/MAPK pathway-driven cancers.

Where is Erasca located?

Erasca is based in San Diego, California.

ShareAdd on Google
Tags: ERAS Viatris Investor Conferences Healthcare Erasca inducement grants Nasdaq precision oncology
Last updated: Aug 10, 2026

Biotech snapshot

Cash runway
$409M liquidity · $9M/mo burn
~42 mo
Minimal dilution risk
Lead asset
NaporafenibPhase 3
Advanced or Metastatic NRAS-mutant Melanoma →

Catalyst track record

+770%
best trade around ERAS's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for ERAS.

See every catalyst's timing & PoA →